AVTR vs. BMRN: Avantor vs. BioMarin Pharmaceutical Stock Comparison
How do Avantor (AVTR) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and BioMarin Pharmaceutical (BMRN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while BMRN is classified in Biotechnology.
| Profile Item | AVTR | BMRN |
|---|---|---|
| Name | Avantor, Inc. | BioMarin Pharmaceutical Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 10.48 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 17, 2019 | July 26, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| Total Return (1Y) | 36.41% | 8.82% |
| Total Return (3Y, Annualized) | -5.02% | -12.54% |
| Total Return (5Y, Annualized) | -16.62% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 35.50% |
| Beta (5Y) | 0.94 | 0.24 |
| Max Drawdown (5Y) | -82.42% | -57.64% |
| Avg. Volume (3M) | 8.56M | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 0.13 |
| Sortino Ratio (1Y) | 1.17 | 0.23 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Avantor (AVTR) reports 5.91%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Avantor (AVTR) reports 5.08%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BioMarin Pharmaceutical (BMRN) at 26.58% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| ROE (TTM) | 5.91% | -0.31% |
| ROA (TTM) | 2.83% | 3.89% |
| Net Margin (TTM) | 5.08% | -0.52% |
| Operating Margin (TTM) | 8.19% | 26.58% |
| Gross Margin (TTM) | 31.59% | 53.21% |
Growth
Revenue Growth
BioMarin Pharmaceutical (BMRN) at 12.87% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
BioMarin Pharmaceutical (BMRN) at -18.55% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 12.87% |
| Revenue Growth (3Y CAGR) | -4.46% | 15.40% |
| EPS Growth (YoY) | -175.00% | -18.55% |
| EPS Growth (3Y CAGR) | -- | 33.89% |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and BioMarin Pharmaceutical (BMRN) at 2.44 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 2.44 |
| Debt / Equity (MRQ) | 0.63 | 0.67 |
| Net Debt / EBITDA | 3.40 | 4.04 |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Avantor (AVTR) trades at 30.94 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
Both Avantor (AVTR) at 1.58 and BioMarin Pharmaceutical (BMRN) at 2.97 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Avantor (AVTR) at 1.80 and BioMarin Pharmaceutical (BMRN) at 1.73 are valued close to their industries’ norm against book — neither stands out from peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | -- |
| P/S Ratio (TTM) | 1.58 | 2.97 |
| P/B Ratio (MRQ) | 1.80 | 1.73 |
| Free Cash Flow Yield (TTM) | 4.21% | -0.15% |